Fact-check
Did Trump Cut Funding to the FDA?
Trump's DOGE-driven layoffs cut nearly 20% of FDA's workforce, and the administration proposed a $400M budget reduction. Congress blocked most of the budget cuts. Verdict: Mostly True.
By The Crosscheck Desk · 2026-08-22
Donald Trump's administration cut funding to the Food and Drug Administration (FDA).
"Donald Trump's administration cut funding to the Food and Drug Administration (FDA)."
The Workforce Cuts
The most direct answer to whether the Trump administration cut the FDA's resources is yes, and the mechanism was staffing, not a budget line. In March 2025, HHS (the Department of Health and Human Services, the FDA's parent agency) announced a sweeping restructuring that eliminated roughly 3,500 positions at the FDA, approximately 19% of the agency's roughly 18,000-person workforce.[1] The move was directed by DOGE (the Department of Government Efficiency), the cost-cutting initiative President Trump established by executive order on his first day in office and placed under Elon Musk's informal direction.[2]
The cuts came in waves. A preliminary round in February 2025 eliminated 89 staffers in the FDA's Human Foods Program, prompting the resignation of Jim Jones, the FDA's Deputy Commissioner for Human Foods, who called the terminations "indiscriminate."[3] The main wave, announced March 27, was broader: drug reviewers, food safety scientists, laboratory staff, chemical safety specialists hired to review potentially unsafe food ingredients, and administrative staff who support product-review pipelines.[1]
HHS Secretary Robert F. Kennedy Jr. framed the reductions as part of a broader organizational consolidation, announcing that his agency would shrink from 82,000 total employees to 62,000, collapsing 28 divisions into 15.[2]
Reinstatements and net effect
After public backlash, the administration reversed some cuts. Politico Pro reported that the FDA reinstated roughly a quarter of the initial DOGE job eliminations.[4] Some food safety scientists and laboratory staff came back; a batch of staffers who process Freedom of Information Act requests were told their firings were rescinded. But many dismissed employees had by then taken other positions or retired, meaning reinstatement offers went unfilled. As of mid-2026, reporting indicates the FDA remains approximately 20% understaffed across the board,[1] with about 2,200 new hires underway but not yet complete.[5]
The Budget Picture
On the formal appropriations side, the story is more complicated, because Congress stepped in.
Trump's proposed FY2026 (fiscal year 2026) budget requested approximately $400 million less in discretionary funding for the FDA, a cut of about 11.4% from the prior year's enacted level.[6] Draft HHS budget documents circulating in May 2025 showed the total requested congressional appropriation for the FDA at roughly $2.9 billion, down from about $3.5 billion in FY2025.[6]
Congress largely rejected those proposed cuts. The FY2026 Agriculture Appropriations Act, enacted November 12, 2025, provided approximately $3.4 billion in discretionary budget authority for the FDA, plus about $3.6 billion in industry user fees, for a total program level of roughly $7.1 billion. That compares to an estimated FY2025 total of approximately $7.0 billion, meaning the enacted FY2026 appropriation is essentially flat with the prior year and substantially above what the administration requested.[7]
Notably, the administration's proposed FY2027 budget moves in the other direction, requesting a total of approximately $7.2 billion for the FDA, a modest 1.9% increase over the FY2026 enacted level, partly driven by higher projected user fee collections.[7]
In short: the administration proposed significant budget cuts to the FDA, but Congress did not pass them. The formal appropriations line declined only marginally from FY2024 to FY2026. The administration's ability to cut the FDA's resources came primarily through workforce reductions, which do not require congressional approval.
Real-World Impact: Drug Approval Delays
The workforce reductions have produced measurable operational consequences. In June 2025, the FDA notified KalVista Pharmaceuticals that it would not meet the PDUFA date (the Congressionally mandated deadline for drug approval decisions) for sebetralstat, a treatment for hereditary angioedema. The stated reason: "heavy workload and limited resources."[8] KalVista's announcement was the first publicly confirmed case of an FDA review extension attributable to DOGE-driven staff cuts.[9] The drug was eventually approved, but the delay drew sharp attention from patient advocates and biotech investors.
Industry surveys tracked broader concern: two-thirds of respondents to a 2025 Managed Healthcare Executive survey said they expected PDUFA deadlines to slip because of FDA staffing reductions. A separate analysis documented a 50% drop in De Novo decisions during 2025, a category of regulatory pathway for novel, lower-risk medical devices that had been a high-throughput function.[1]
Food safety oversight has also drawn scrutiny. Reporting in early 2026 documented concerns from food safety researchers and former inspectors about the FDA's capacity to conduct routine inspections at the pace required by the Food Safety Modernization Act.[10]
FDA Commissioner Marty Makary publicly maintained that the agency was "on track to meet all PDUFA targets" and that morale was "good and improving." That statement came shortly before the KalVista delay was disclosed.[1]
The Right Question to Ask
The claim "Trump cut funding to the FDA" conflates two distinct things, and separating them is where the factual record sheds real light.
Question 1: Did the administration cut the FDA's formal budget appropriation? The answer is: proposed yes, enacted mostly no. Congress blocked the largest proposed cut ($400M) and held the total program level roughly flat. If a reader takes "funding" to mean only the statutory appropriated amount, the claim overstates what happened.
Question 2: Did the administration reduce the FDA's operational capacity? The answer here is clearly yes. Eliminating 3,500 positions, net understaffing of ~20% a year later, and at least one documented drug-approval delay attributed to "limited resources" all demonstrate that the FDA's actual ability to carry out its mission was reduced. Workforce accounts for the large majority of any government agency's operating cost; cutting the workforce by 19% is a resource cut whether or not the line item in a budget document changed.
The better-framed question is the second one, and the evidence answers it: the Trump administration reduced the FDA's operational resources substantially, primarily through workforce reductions. The formal appropriation picture is secondary and more favorable to the administration. Both facts belong in the same sentence.
| Actor | Outcome | Why |
|---|---|---|
| FDA career staff | Lost | 3,500 positions eliminated; ~20% net understaffing; institutional knowledge departed |
| Patients awaiting drug approvals | Mixed | Some approval delays confirmed; most PDUFA dates still met; long-term review capacity uncertain |
| Pharmaceutical & device companies | Mixed | Regulatory uncertainty and some delays; but user fees mostly intact and total FDA program level held near prior-year levels |
| Congress | Won (partially) | Rejected administration's proposed $400M budget cut; enacted FDA funding near prior-year levels |
| Trump administration / DOGE | Mixed | Achieved workforce reduction goal; formal budget proposal blocked by Congress; reorganization codified for Oct 2026 |
Administration officials argued that the FDA's workforce had grown substantially over the prior decade, with administrative and support functions outpacing scientific work. HHS Secretary Kennedy pointed to what he called an "administrative bloat" problem: too many staff in management, communications, and coordination roles relative to front-line reviewers. The reorganization plan, known internally as "Simple Reform," sought to centralize human resources, finance, and IT functions across the FDA's nine program centers into a single shared-services model, eliminating redundant overhead. The administration also noted that the FDA's total program level remained above pre-pandemic levels even after the workforce reductions. Commissioner Makary has argued that a leaner, better-organized agency could be more efficient than a larger one with duplicated administrative structures. This argument has some theoretical merit for administrative functions, though former FDA acting commissioner Janet Woodcock called the approach a "mindless" oversimplification for an agency whose specialized scientific centers require distinct expertise.[5]
The Trump administration reduced the FDA's operational resources in ways that are well documented and consequential. Roughly 3,500 positions were eliminated, leaving the agency about 20% understaffed a year later, and at least one drug approval deadline was missed with "limited resources" cited as the cause. The administration also proposed cutting the FDA's discretionary appropriation by $400 million, or 11.4%.
What the claim leaves out: Congress blocked the largest proposed budget cuts, enacting FY2026 appropriations roughly flat with prior years. The administration's proposed FY2027 budget would modestly increase the FDA's total program level. Some laid-off staff were reinstated, and new hiring is underway. The claim is accurate on the workforce reduction, which is real and ongoing, but "cut funding" in a strict budget sense understates Congress's role in limiting the damage. The cleaner, more accurate claim is: Trump's administration cut the FDA's workforce and proposed major budget reductions, most of which Congress rejected.
Every load-bearing figure in this article was traced to the specific source passage that supports it. The 19% workforce figure is derived from 3,500 eliminations against an FDA workforce of roughly 18,000, consistent with reporting describing this as "nearly 20%." The $400 million/$11.4% proposed cut comes from the BioPharma Dive analysis of the draft HHS budget. The FY2026 enacted figures ($3.4B discretionary + $3.6B user fees) come from the FederalBudgetIQ and Faegre Drinker analyses of the enacted appropriation law. The "roughly a quarter reinstated" figure is from a Politico Pro report.[4]
- October 1, 2026 — FDA "Simple Reform" takes effect. The reorganization that consolidates administrative functions and de-specializes field inspectors becomes official. Watch for data on whether inspection rates and review timelines hold, improve, or deteriorate under the new structure.
- FY2027 appropriations process (fall 2026). The Trump administration has proposed $7.2 billion for FDA in FY2027, a slight overall increase from FY2026, but with continued downward pressure on discretionary funding offset by higher user fees. Whether Congress accepts or reshapes that proposal will determine whether the partial FY2026 recovery holds.
- PDUFA and user fee reauthorizations (2027). Major PDUFA (Prescription Drug User Fee Act) agreements expire in September 2027. Their reauthorization will determine whether industry user fees, which constitute roughly half of FDA's total program level, are renewed, restructured, or reduced. RFK Jr.'s statements expressing skepticism about industry funding of the FDA have raised the stakes.
- Drug approval rate data (ongoing). The 50% drop in De Novo decisions in 2025 is a leading indicator. Tracking whether that rate recovers in 2026 and 2027 will show whether the new hires can offset the institutional knowledge lost in the initial cuts.
What Is the Claim?
People have been asking: Did Donald Trump's administration cut funding to the FDA? The FDA, or the Food and Drug Administration, is the U.S. government agency that approves new medicines, checks food safety, and oversees medical devices.
We rated this claim Mostly True.
What Actually Happened to FDA Staff?
Yes, the Trump administration cut the FDA's workforce. In March 2025, the FDA's parent department, HHS (the U.S. Department of Health and Human Services), announced it was eliminating about 3,500 FDA jobs. That was about 19 out of every 100 FDA workers.
The cuts came from DOGE, the Department of Government Efficiency. DOGE is a cost-cutting effort President Trump created on his first day in office, run informally by Elon Musk.
The first round of cuts, in February 2025, removed 89 workers from the FDA's food safety division. The FDA's deputy head of food safety quit, calling the firings indiscriminate.
The bigger round, on March 27, 2025, cut drug reviewers, food safety scientists, lab workers, and support staff.
Some workers were later brought back. About one in four of those fired were eventually reinstated. But many had already taken other jobs or retired, so the offers were often too late. As of mid-2026, the FDA was still about 20% short of full staffing.
What About the FDA's Budget?
The budget picture is more complicated, because Congress stepped in.
President Trump proposed cutting the FDA's yearly budget by about $400 million in fiscal year 2026, roughly an 11% reduction.
Congress said no. Lawmakers passed a spending law in November 2025 that kept the FDA's discretionary funding at about $3.4 billion, close to the prior year's level. Add in the money that drug companies pay the FDA in user fees, and the total came to roughly $7.1 billion for 2026, about the same as 2025.
The administration proposed big budget cuts, but Congress blocked most of them. The FDA's formal budget did not fall dramatically. What fell was its workforce.
Did the Cuts Have Real Effects?
Yes. In June 2025, the FDA missed a legal deadline to decide on a new medicine. The drug was sebetralstat, made by KalVista, for a rare genetic disorder called hereditary angioedema. The FDA said it missed the deadline because of a 'heavy workload and limited resources.' The drug was eventually approved, but this was the first confirmed case where a missed deadline was tied to the DOGE staff cuts.
A survey of healthcare professionals found that two-thirds expected similar delays to grow. There was also a 50% drop in a type of medical device approval called De Novo decisions during 2025.
Food safety experts raised concerns too. The FDA is required by law to inspect food facilities regularly. Reporters documented evidence that inspection capacity was under strain.
The Right Way to Understand This
The phrase 'cut funding to the FDA' can mean two different things. If it means 'cut the FDA's formal budget,' that is only partly true. Congress kept the budget roughly flat. If it means 'reduced the FDA's ability to do its job,' that is clearly true. Cutting one in five workers makes it harder for the agency to function, even if the budget numbers on paper did not change as much.
The Case for the Cuts
Administration officials argued that the FDA had too many administrative workers. Secretary Robert F. Kennedy Jr. said the cuts targeted management layers. FDA Commissioner Marty Makary said the agency was getting leaner and more effective. A new plan called 'Simple Reform' aimed to combine office functions across the FDA's nine divisions. Former FDA leaders said this risked removing specialized expertise that takes years to rebuild.
Verdict
The Trump administration reduced the FDA's resources in significant, documented ways. About 3,500 workers were eliminated. A year later, the agency was still 20% short of its needed staff. At least one drug approval was delayed because of 'limited resources.' The administration also tried to cut the FDA's formal budget by $400 million, but Congress blocked most of that.
The claim is Mostly True. The workforce cuts are real and documented. The formal budget cuts were mostly stopped by Congress. A fully accurate statement: Trump's administration cut the FDA's workforce significantly and proposed major budget reductions, most of which Congress rejected.
What to Watch
- October 1, 2026: The FDA's new organizational plan takes effect, changing how inspectors are assigned. Watch for data on whether drug review times stay on track.
- Fall 2026: Congress will debate the FDA's proposed 2027 budget. The Trump administration proposed a slight overall increase, but with less direct government funding and more from industry fees.
- September 2027: Major PDUFA agreements expire. These laws let drug companies pay fees for faster reviews and fund about half of FDA's budget. RFK Jr. has expressed doubts about this system.
- Ongoing: Watch drug approval rates in 2026 and 2027. The 50% drop in De Novo decisions in 2025 is an early warning sign of staffing effects.
Sources
- In FDA job cuts, experts see threat of far-reaching impact
- The Trump administration's NIH and FDA cuts will negatively impact patients
- A 2025 Timeline of U.S. Federal Food Safety Changes Under the Trump Admin
- FDA reinstated roughly a quarter of initial DOGE job cuts
- The FDA Is Officially Codifying DOGE-Era Changes
- FDA cuts outlined in draft HHS budget
- FDA-Related Legislative and Regulatory Proposals and Funding Change: The President's FY27 Budget
- FDA to miss approval deadline for KalVista drug due to 'resource constraints'
- KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA
- FDA and USDA staff cuts under Trump raise food safety risks
- FDA Missed PDUFA Date Due To 'Limited Resources,' Sponsor Says
- FDA Rebuilding After DOGE Cuts: Former Regulators Speak Out
